The outcomes in Olutasidenib-treated patients from the 2102-HEM-101 single-arm trial were compared to a real-world external control arm of Ivosidenib, suggestive of favorable effectiveness of Olutasidenib for patients with IDH1-mutant AML who are R/R to a Venetoclax-based regimen [48]. The gene discussed is IDH1; the disease is acute myeloid leukemia.